PMID: 6105889Aug 13, 1980Paper

Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite: possible involvement of S-nitrosothiols

Biochimica Et Biophysica Acta
L J Ignarro, C A Gruetter

Abstract

Glyceryl trinitrate specifically required cysteine, whereas NaNO2 at concentrations less than 10 mM required one of several thiols or ascorbate, to activate soluble guanylate cyclase from bovine coronary artery. However, guanylate cyclase activation by nitroprusside or nitric oxide did not require the addition of thiols or ascorbate. Whereas various thiols enhanced activation by nitroprusside, none of the thiols tested enhanced activation by nitric oxide. S-Nitrosocysteine, which is formed when cysteine reacts with either NO-2 or nitric oxide, was a potent activator of guanylate cyclase. Similarly, micromolar concentrations of the S-nitroso derivatives of penicillamine, GSH and dithiothreitol, prepared by reacting the thiol with nitric oxide, activated guanylate cyclase. Guanylate cyclase activation by S-nitrosothiols resembled that by nitric oxide and nitroprusside in that activation was inhibited by methemoglobin, ferricyanide and methylene blue. Similarly, guanylate cyclase activation by glyceryl trinitrae plus cysteine, and by NaNO2 plus either a thiol or ascorbate, was inhibited by methemoglobin, ferricyanide and methylene blue. These data suggest that the activation of guanylate cyclase by each of the compounds tested may...Continue Reading

References

Oct 4, 1976·Biochemical and Biophysical Research Communications·N MikiK Kuriyama
Apr 25, 1977·Biochemical and Biophysical Research Communications·N MikiK Kuriyama
Jan 1, 1977·Annual Review of Biochemistry·N D Goldberg, M K Haddox
Aug 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·W P ArnoldF Murad
Jan 1, 1976·Annual Review of Pharmacology and Toxicology·P Needleman

❮ Previous
Next ❯

Citations

Aug 1, 1991·Naunyn-Schmiedeberg's Archives of Pharmacology·K SchrörI Woditsch
Apr 1, 1982·Naunyn-Schmiedeberg's Archives of Pharmacology·W R KukovetzG Pöch
Oct 1, 1994·Cardiovascular Drugs and Therapy·K E Torfgård, J Ahlner
Aug 1, 1989·Cardiovascular Drugs and Therapy·T M IbrahimS Degre
Jul 1, 1995·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·M FratelliP Ghezzi
Dec 14, 2011·Cell Biochemistry and Biophysics·Enika Nagababu, Joseph M Rifkind
Apr 20, 1984·European Journal of Pharmacology·T Kamitani
Apr 23, 1985·European Journal of Pharmacology·C A Gruetter, S M Lemke
Mar 11, 1986·European Journal of Pharmacology·K Schmidt, W R Kukovetz
Dec 15, 1987·European Journal of Pharmacology·E A KowalukH L Fung
Jul 3, 1990·European Journal of Pharmacology·H SchröderK Schrör
Feb 11, 1994·European Journal of Pharmacology·C L ZhangJ D Horowitz
Jun 9, 1990·Lancet
Aug 1, 1996·Neurochemistry International·V L Dawson, T M Dawson
Jan 1, 1982·Comparative Biochemistry and Physiology. C: Comparative Pharmacology·P MensiG Schenone
Jul 1, 1988·Neuroscience·G Garthwaite, J Garthwaite
Sep 1, 1982·Toxicology Letters·T KobayashiS Nagasawa
Aug 1, 1993·Journal of the American College of Cardiology·I T MeredithR W Harper
Jun 1, 1996·Journal of Chemical Neuroanatomy·V L Dawson, T M Dawson
Dec 1, 1991·Trends in Cardiovascular Medicine·J S Stamler, J Loscalzo
Jun 7, 2005·Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology·Anne JeffersDaniel B Kim-Shapiro
Mar 3, 2004·Free Radical Biology & Medicine·Mark T GladwinRakesh P Patel
Nov 6, 2001·Clinica Chimica Acta; International Journal of Clinical Chemistry·Y TianW H Betts
Jul 25, 1997·Atherosclerosis·G R UpchurchJ Loscalzo
Sep 24, 2002·Pharmacology & Therapeutics·B J Nevin, K J Broadley
Jun 23, 2001·Biochimica Et Biophysica Acta·J J DoelR Harrison
Jun 12, 2003·Journal of the American College of Cardiology·John D Horowitz
Aug 7, 1998·Journal of Pharmacological and Toxicological Methods·J PatariczaJ G Papp
Oct 17, 2002·Nitric Oxide : Biology and Chemistry·Anatoly F VaninJean-Claude Stoclet
Dec 10, 1999·British Journal of Pharmacology·M VillarroyaA G García
Jun 6, 2002·Proceedings of the National Academy of Sciences of the United States of America·Zhiqiang ChenJonathan S Stamler
Jun 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Louis J Ignarro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.